Since ancient times, the egg has been regarded as a symbol of new life and has been associated with springtime celebrations, such as Easter and Passover. But, even during festive occasions, eggs can cause food poisoning (also called foodborne illness) if they are not handled properly. That’s why the U.S. Food and Drug Administration (FDA) reminds consumers to handle fresh eggs safely during their springtime celebrations and throughout the year.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7231951-u-s-fda-egg-safety/
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism
An injury ends Laura Nelson’s career as a surgeon. Now, as Vice President of a pharmaceutical company, Laura works to finalize the approval of a groundbreaking new drug. But her efforts are being thwarted by a malicious FDA employee who will stop at nothing to prevent the approval, and Laura is standing directly in his path. Find out more about the author here- http://patriciagussin.com/ and check out the book here http://oceanviewpub.com/after-the-fall/. After the Fall by Patricia Gussin. Thriller
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
Como preparación para el 4 julio y los meses veraniegos, período en el cual aumentan los casos de intoxicación alimentaria, el Ad Council y el Servicio de Inocuidad e Inspección de los Alimentos del Departamento de Agricultura de los Estados Unidos, en asociación con la Administración de Alimentos y Medicinas de los Estados Unidos (FDA) y los Centros para el Control y la Prevención de Enfermedades (CDC), prosiguen con su campaña de servicio público Familias Preparando Alimentos Adecuadamente a nivel nacional, el primer esfuerzo en multimedios diseñado para aumentar el grado de conciencia sobre los riesgos de las enfermedades transmitidas por los alimentos (o intoxicación alimentaria) en el hogar. Nuevos anuncios de servicio público (PSA), colocados en vallas, marquesinas de autobuses y otras localidades en exteriores a lo largo y ancho del país, están siendo distribuidos a medios informativos de todo el país y el spot televisivo “Chill” (Refrigere) se transmitirá a través de la cadena Checkout TV Network en 600 en tiendas de Walmart a nivel nacional.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56942-ad-council-usda-hhs-food-safe-families-public-service-campaign
In preparation for July 4th and the summer months when instances of food poisoning increase, the Ad Council and the U.S. Department of Agriculture’s Food Safety and Inspection Service, in partnership with the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), are continuing their national Food Safe Families public service campaign, the first multimedia effort designed to raise awareness of the risks of foodborne illness (or food poisoning) in the home.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56338-ad-council-usda-hhs-food-safe-families-public-service-campaign
Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States.
Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Nearly three in four American voters (74 percent) favor increasing federal funding for cancer research, according to the results of a new national survey conducted on behalf of the American Association for Cancer Research (AACR). The survey results were released today in conjunction with the AACR’s fifth annual Cancer Progress Report. The report highlights how federally funded research can power progress against cancer and urges Congress and the administration to implement a strategy for providing annual budget increases of at least 7 percent for the National Institutes of Health (NIH), National Cancer Institute (NCI), and U.S. Food and Drug Administration (FDA) in fiscal year 2016 and thereafter.
The national survey, which was conducted by Hart Research Associates and Public Opinion Strategies, shows that five out of every six voters recognize what the AACR Cancer Progress Report 2015 details: that progress is being made against cancer.
To view the multimedia release go to:
http://www.multivu.com/players/English/7613551-aacr-cancer-research-survey/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
